Theralase Technologies (CVE:TLT) Shares Up 13.2% – Time to Buy?

Theralase Technologies Inc. (CVE:TLT) shares traded up 13.2% during mid-day trading on Thursday. The stock traded as high as C$0.22 and last traded at C$0.21. Approximately 284,162 shares were traded during trading, an increase of 20% from the average daily volume of 236,993 shares. The stock had previously closed at C$0.19.

Theralase Technologies Stock Down 4.5%

The company has a debt-to-equity ratio of 2.17, a current ratio of 5.48 and a quick ratio of 3.40. The company has a market cap of C$65.20 million, a P/E ratio of -15.00 and a beta of -1.01. The stock has a 50-day moving average of C$0.18 and a 200 day moving average of C$0.23.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.